NL-OMON25345尚未招募不适用
A randomized phase III study in previously untreated patients with biological high-risk CLL: Fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumab.
Dr. C.H. GeislerRigshospitaletDept. of Hematology (L 4042)Blegdamsvej 9DK-2100 CopenhagenDenmarkTel: 0045 35451146Fax: 0045 35454283e-mail:geisler@rh.dk0 个研究点目标入组 300 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 300
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Biological high-risk CLL;
- •2. Patients with symptomatic stage A, symptomatic stage B or stage C;
排除标准
- •1. WHO performance status >= 3, unless related to CLL;
- •2. Intolerance of exogenous protein administration;
研究者
相似试验
已完成
不适用
A randomized phase III study in previously untreated patients with biological high-risk CLL: fludarabine and cyclophosphamide (FC) versus FC and low-dose alemtuzumabCancerLeukaemiaISRCTN25180151Rigshospitalet (Denmark)300
进行中（未招募）
1 期
A randomized phase III study in previously untreated patients with biological high-risk CLL: Fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumabEUCTR2005-000309-75-CZHOVON CLL Group300
进行中（未招募）
1 期
Randomisierte Phase III Studie für Patienten mit Multiplem Myelom zur Untersuchung zweier Therapieschemata einer Bortezomib-basierten Induktionsthearpie und einer Lenalidomid-Konsolidierungstherapie gefolgt von einer Erhaltungstherapie mit Lenalidomidmultiple myeloma (symptomatic, newly diagnosed)EUCTR2010-019173-16-DEniversity Hospital Heidelberg604
招募中
不适用
OROCSON study: Late Onset Recurrent Ovarian Cancer: Surgery Or Not.NL-OMON27781700
已完成
3 期
The MM5 trial: evaluation of two regimens of bortezomib-based induction therapy and of lenalidomide consolidation followed by lenalidomide maintenance treatment in patients with multiple myelomaMultiple myelomaCancerISRCTN05622749niversity Hospital Heidelberg (Universitätsklinikum Heidelberg) (Germany)504